|
1
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
3
|
Bookman MA, Brady MF, McGuire WP, et al:
Evaluation of new platinum-based treatment regimens in
advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic
Cancer Intergroup. J Clin Oncol. 27:1419–1425. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Claus EB, Schildkraut JM, Thompson WD and
Risch NJ: The genetic attributable risk of breast and ovarian
cancer. Cancer. 77:2318–2324. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Antoniou A, Pharoah PD, Narod S, et al:
Average risks of breast and ovarian cancer associated with BRCA1 or
BRCA2 mutations detected in case Series unselected for family
history: a combined analysis of 22 studies. Am J Hum Genet.
72:1117–1130. 2003. View
Article : Google Scholar
|
|
6
|
Tian C, Ambrosone CB, Darcy KM, Krivak TC,
Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H and
DeLoia JA: Common variants in ABCB1, ABCC2 and ABCG2 genes and
clinical outcomes among women with advanced stage ovarian cancer
treated with platinum and taxane-based chemotherapy: a Gynecologic
Oncology Group study. Gynecol Oncol. 124:575–581. 2012. View Article : Google Scholar
|
|
7
|
Darcy KM, Brady WE, Blancato JK, Dickson
RB, Hoskins WJ, McGuire WP and Birrer MJ: Prognostic relevance of
c-MYC gene amplification and polysomy for chromosome 8 in
suboptimally-resected, advanced stage epithelial ovarian cancers: a
Gynecologic Oncology Group study. Gynecol Oncol. 114:472–479. 2009.
View Article : Google Scholar
|
|
8
|
Tuefferd M, Couturier J, Penault-Llorca F,
Vincent-Salomon A, Broët P, Guastalla JP, Allouache D, Combe M,
Weber B, Pujade-Lauraine E and Camilleri-Broët S: HER2 status in
ovarian carcinomas: a multicenter GINECO study of 320 patients.
PLoS One. 2:e11382007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baylin SB and Ohm JE: Epigenetic gene
silencing in cancer - a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ushijima T and Asada K: Aberrant DNA
methylation in contrast with mutations. Cancer Sci. 101:300–305.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoo CB and Jones PA: Epigenetic therapy of
cancer: past, present and future. Nat Rev Drug Discov. 5:37–50.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Russo VEA, Riggs AD and Martienssen RA:
Epigenetic mechanisms of gene regulation. Cold Spring Harbor
Laboratory Press; Plainview, NY: 1996
|
|
13
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wilting RH and Dannenberg JH: Epigenetic
mechanisms in tumorigenesis, tumor cell heterogeneity and drug
resistance. Drug Resist Updat. 15:21–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koukoura O, Sifakis S and Spandidos DA:
DNA methylation in the human placenta and fetal growth (Review).
Mol Med Rep. 5:883–839. 2012.PubMed/NCBI
|
|
16
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weber M and Schubeler D: Genomic patterns
of DNA methylation: targets and function of an epigenetic mark.
Curr Opin Cell Biol. 19:273–280. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bird AP and Wolffe AP: Methylation-induced
repression - belts, braces, and chromatin. Cell. 99:451–454. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Costello JF and Plass C: Methylation
matters. J Med Genet. 38:285–303. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Catteau A, Harris WH, Xu CF and Solomon E:
Methylation of the BRCA1 promoter region in sporadic breast and
ovarian cancer: correlation with disease characteristics. Oncogene.
18:1957–1965. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar
|
|
22
|
Esteller M, Silva JM, Dominguez G, et al:
Promoter hypermethylation and BRCA1 inactivation in sporadic breast
and ovarian tumors. J Natl Cancer Inst. 92:564–569. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baylin SB and Chen WY: Aberrant gene
silencing in tumor progression: implications for control of cancer.
Cold Spring Harb Symp Quant Biol. 70:427–433. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Horak P, Pils D, Haller G, et al:
Contribution of epigenetic silencing of tumor necrosis
factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL
resistance and ovarian cancer. Mol Cancer Res. 3:335–343. 2005.
View Article : Google Scholar
|
|
25
|
Petrocca F, Iliopoulos D, Qin HR, et al:
Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer.
Cancer Res. 66:10287–10291. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu Y, Fujii S, Yuan J, et al: Epigenetic
regulation of ARHI in breast and ovarian cancer cells. Ann NY Acad
Sci. 983:268–277. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Baldwin RL, Nemeth E, Tran H, et al: BRCA1
promoter region hypermethylation in ovarian carcinoma: a
population-based study. Cancer Res. 60:5329–5333. 2000.PubMed/NCBI
|
|
28
|
Hilton JL, Geisler JP, Rathe JA,
Hattermann-Zogg MA, DeYoung B and Buller RE: Inactivation of BRCA1
and BRCA2 in ovarian cancer. J Natl Cancer Inst. 94:1396–1406.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li ML and Greenberg RA: Links between
genome integrity and BRCA1 tumor suppression. Trends Biochem Sci.
37:418–424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McCoy ML, Mueller CR and Roskelley CD: The
role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic
epithelial ovarian cancer. Reprod Biol Endocrinol. 1:722003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rzepecka IK, Szafron L, Stys A, et al:
High frequency of allelic loss at the BRCA1 locus in ovarian
cancers: clinicopathologic and molecular associations. Cancer
Genet. 205:94–100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Strathdee G, Appleton K, Illand M, et al:
Primary ovarian carcinomas display multiple methylator phenotypes
involving known tumor suppressor genes. Am J Pathol. 158:1121–1127.
2001. View Article : Google Scholar
|
|
33
|
Chan KY, Ozcelik H, Cheung AN, Ngan HY and
Khoo US: Epigenetic factors controlling the BRCA1 and BRCA2 genes
in sporadic ovarian cancer. Cancer Res. 62:4151–4156.
2002.PubMed/NCBI
|
|
34
|
Wang YQ, Yan Q, Zhang JR, Li SD, Yang YX
and Wan XP: Epigenetic inactivation of BRCA1 through promoter
hypermethylation in ovarian cancer progression. J Obstet Gynaecol
Res. 39:549–554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang C, Horiuchi A, Imai T, et al:
Expression of BRCA1 protein in benign, borderline, and malignant
epithelial ovarian neoplasms and its relationship to methylation
and allelic loss of the BRCA1 gene. J Pathol. 202:215–223. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan
HY: Differential DNA methylation profiles in gynecological cancers
and correlation with clinico-pathological data. BMC Cancer.
6:2122006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bol GM, Suijkerbuijk KP, Bart J, Vooijs M,
van der Wall E and van Diest PJ: Methylation profiles of hereditary
and sporadic ovarian cancer. Histopathology. 57:363–370. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rathi A, Virmani AK, Schorge JO, et al:
Methylation profiles of sporadic ovarian tumors and nonmalignant
ovaries from high-risk women. Clin Cancer Res. 8:3324–3331.
2002.PubMed/NCBI
|
|
39
|
Kontorovich T, Cohen Y, Nir U and Friedman
E: Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53
as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation
carriers. Breast Cancer Res Treat. 116:195–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Blasi MF, Ventura I, Aquilina G, et al: A
human cell-based assay to evaluate the effects of alterations in
the MLH1 mismatch repair gene. Cancer Res. 66:9036–9044. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jiricny J and Nyström-Lahti M: Mismatch
repair defects in cancer. Curr Opin Genet Dev. 10:157–161. 2000.
View Article : Google Scholar
|
|
42
|
Kunkel TA and Erie DA: DNA mismatch
repair. Annu Rev Biochem. 74:681–710. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Murphy MA and Wentzensen N: Frequency of
mismatch repair deficiency in ovarian cancer: a systematic review.
This article is a US Government work and, as such, is in the public
domain of the United States of America. Int J Cancer.
129:1914–1922. 2011. View Article : Google Scholar
|
|
44
|
Zhang H, Zhang S, Cui J, Zhang A, Shen L
and Yu H: Expression and promoter methylation status of mismatch
repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Aust N Z
J Obstet Gynaecol. 48:505–509. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Watanabe Y, Ueda H, Etoh T, et al: A
change in promoter methylation of hMLH1 is a cause of acquired
resistance to platinum-based chemotherapy in epithelial ovarian
cancer. Anticancer Res. 27:1449–1452. 2007.
|
|
46
|
Barton CA, Hacker NF, Clark SJ and O’Brien
PM: DNA methylation changes in ovarian cancer: implications for
early diagnosis, prognosis and treatment. Gynecol Oncol.
109:129–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ozdemir F, Altinisik J, Karateke A,
Coksuer H and Buyru N: Methylation of tumor suppressor genes in
ovarian cancer. Exp Ther Med. 4:1092–1096. 2012.PubMed/NCBI
|
|
48
|
Moselhy SS, Kumosani TA, Kamal IH, Jalal
JA, Abdul Jabaar HS and Dalol A: Hypermethylation of P15, P16, and
E-cadherin genes in ovarian cancer. Toxicol Ind Health. Apr
9–2013.(Epub ahead of print).
|
|
49
|
Dhillon VS, Young AR, Husain SA and Aslam
M: Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour
suppressor genes in granulosa cell tumours (GCTs) of ovarian
origin. Br J Cancer. 90:874–881. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Staub J, Chien J, Pan Y, et al: Epigenetic
silencing of HSulf-1 in ovarian cancer: implications in
chemoresistance. Oncogene. 26:4969–4978. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Samuel S and Naora H: Homeobox gene
expression in cancer: insights from developmental regulation and
deregulation. Eur J Cancer. 41:2428–2437. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kelly ZL, Michael A, Butler-Manuel S,
Pandha HS and Morgan RG: HOX genes in ovarian cancer. J Ovarian
Res. 4:162011. View Article : Google Scholar
|
|
53
|
Montavon C, Gloss BS, Warton K, et al:
Prognostic and diagnostic significance of DNA methylation patterns
in high grade serous ovarian cancer. Gynecol Oncol. 124:582–588.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Widschwendter M, Apostolidou S, Jones AA,
et al: HOXA methylation in normal endometrium from premenopausal
women is associated with the presence of ovarian cancer: a proof of
principle study. Int J Cancer. 125:2214–2218. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Swisher EM, Gonzalez RM, Taniguchi T, et
al: Methylation and protein expression of DNA repair genes:
association with chemotherapy exposure and survival in sporadic
ovarian and peritoneal carcinomas. Mol Cancer. 8:482009. View Article : Google Scholar
|
|
56
|
Ibanez de Caceres I, Battagli C, Esteller
M, et al: Tumor cell-specific BRCA1 and RASSF1A hypermethylation in
serum, plasma, and peritoneal fluid from ovarian cancer patients.
Cancer Res. 64:6476–6481. 2004.PubMed/NCBI
|
|
57
|
Makarla PB, Saboorian MH, Ashfaq R, et al:
Promoter hypermethylation profile of ovarian epithelial neoplasms.
Clin Cancer Res. 11:5365–5369. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tam KF, Liu VW, Liu SS, et al: Methylation
profile in benign, borderline and malignant ovarian tumors. J
Cancer Res Clin Oncol. 133:331–341. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pattamadilok J, Huapai N, Rattanatanyong
P, et al: LINE-1 hypomethylation level as a potential prognostic
factor for epithelial ovarian cancer. Int J Gynecol Cancer.
18:711–717. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Widschwendter M, Jiang G, Woods C, et al:
DNA hypomethylation and ovarian cancer biology. Cancer Res.
64:4472–4480. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Honda H, Pazin MJ, Ji H, Wernyj RP and
Morin PJ: Crucial roles of Sp1 and epigenetic modifications in the
regulation of the CLDN4 promoter in ovarian cancer cells. J Biol
Chem. 281:21433–21444. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lee PS, Teaberry VS, Bland AE, et al:
Elevated MAL expression is accompanied by promoter hypomethylation
and platinum resistance in epithelial ovarian cancer. Int J Cancer.
126:1378–1389. 2010.PubMed/NCBI
|
|
63
|
Woloszynska-Read A, James SR, Link PA, Yu
J, Odunsi K and Karpf AR: DNA methylation-dependent regulation of
BORIS/CTCFL expression in ovarian cancer. Cancer Immun.
7:212007.PubMed/NCBI
|
|
64
|
Izutsu N, Maesawa C, Shibazaki M, et al:
Epigenetic modification is involved in aberrant expression of class
III β-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol.
32:1227–1235. 2008.PubMed/NCBI
|
|
65
|
Balch C, Matei DE, Huang TH and Nephew KP:
Role of epigenomics in ovarian and endometrial cancers.
Epigenomics. 2:419–447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Strathdee G, Davies BR, Vass JK, Siddiqui
N and Brown R: Cell type-specific methylation of an intronic CpG
island controls expression of the MCJ gene. Carcinogenesis.
25:693–701. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Strathdee G, Vass JK, Oien KA, Siddiqui N,
Curto-Garcia J and Brown R: Demethylation of the MCJ gene in stage
III/IV epithelial ovarian cancer and response to chemotherapy.
Gynecol Oncol. 97:898–903. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gupta A, Godwin AK, Vanderveer L, Lu A and
Liu J: Hypomethylation of the synuclein gamma gene CpG island
promotes its aberrant expression in breast carcinoma and ovarian
carcinoma. Cancer Res. 63:664–673. 2003.PubMed/NCBI
|
|
69
|
Teschendorff AE, Menon U, Gentry-Maharaj
A, et al: An epigenetic signature in peripheral blood predicts
active ovarian cancer. PLoS One. 4:e82742009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wei SH, Balch C, Paik HH, et al:
Prognostic DNA methylation biomarkers in ovarian cancer. Clin
Cancer Res. 12:2788–2794. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wei SH, Chen CM, Strathdee G, et al:
Methylation microarray analysis of late-stage ovarian carcinomas
distinguishes progression-free survival in patients and identifies
candidate epigenetic markers. Clin Cancer Res. 8:2246–2252.
2002.
|
|
72
|
Zhang Q, Hu G, Yang Q, et al: A multiplex
methylation-specific PCR assay for the detection of early-stage
ovarian cancer using cell-free serum DNA. Gynecol Oncol.
130:132–139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Melnikov A, Zaborina O, Dhiman N,
Prabhakar BS, Chakrabarty AM and Hendrickson W: Clinical and
environmental isolates of Burkholderia cepacia exhibit
differential cytotoxicity towards macrophages and mast cells. Mol
Microbiol. 36:1481–1493. 2000.
|
|
74
|
Ozols RF: Systemic therapy for ovarian
cancer: current status and new treatments. Semin Oncol. 33:S3–S11.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Balch C, Huang TH, Brown R and Nephew KP:
The epigenetics of ovarian cancer drug resistance and
resensitization. Am J Obstet Gynecol. 191:1552–1572. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Su HY, Lai HC, Lin YW, et al: Epigenetic
silencing of SFRP5 is related to malignant phenotype and
chemoresistance of ovarian cancer through Wnt signaling pathway.
Int J Cancer. 127:555–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Nicholson LJ, Smith PR, Hiller L, et al:
Epigenetic silencing of argininosuccinate synthetase confers
resistance to platinum-induced cell death but collateral
sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer.
125:1454–1463. 2009. View Article : Google Scholar
|
|
78
|
Strathdee G, MacKean MJ, Illand M and
Brown R: A role for methylation of the hMLH1 promoter in loss of
hMLH1 expression and drug resistance in ovarian cancer. Oncogene.
18:2335–2341. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yap OW, Bhat G, Liu L and Tollefsbol TO:
Epigenetic modifications of the estrogen receptor beta gene in
epithelial ovarian cancer cells. Anticancer Res. 29:139–144.
2009.PubMed/NCBI
|
|
80
|
Lehmann U, Celikkaya G, Hasemeier B,
Langer F and Kreipe H: Promoter hypermethylation of the
death-associated protein kinase gene in breast cancer is associated
with the invasive lobular subtype. Cancer Res. 62:6634–6638.
2002.PubMed/NCBI
|
|
81
|
Curley MD, Therrien VA, Cummings CL, et
al: CD133 expression defines a tumor initiating cell population in
primary human ovarian cancer. Stem Cells. 27:2875–2883.
2009.PubMed/NCBI
|
|
82
|
Li M, Balch C, Montgomery JS, et al:
Integrated analysis of DNA methylation and gene expression reveals
specific signaling pathways associated with platinum resistance in
ovarian cancer. BMC Med Genomics. 2:342009. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Laird PW: The power and the promise of DNA
methylation markers. Nat Rev Cancer. 3:253–266. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ivanov M, Kacevska M and Ingelman-Sundberg
M: Epigenomics and interindividual differences in drug response.
Clin Pharmacol Ther. 92:727–736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Santi DV, Norment A and Garrett CE:
Covalent bond formation between a DNA-cytosine methyltransferase
and DNA containing 5-azacytosine. Proc Natl Acad Sci USA.
81:6993–6997. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kaminskas E, Farrell A, Abraham S, et al:
Approval summary: azacitidine for treatment of myelodysplastic
syndrome subtypes. Clin Cancer Res. 11:3604–3608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Issa JP, Garcia-Manero G, Giles FJ, et al:
Phase 1 study of low-dose prolonged exposure schedules of the
hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in
hematopoietic malignancies. Blood. 103:1635–1640. 2004.PubMed/NCBI
|
|
88
|
Issa JP, Gharibyan V, Cortes J, et al:
Phase II study of low-dose decitabine in patients with chronic
myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol.
23:3948–3956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y
and Dahiya R: Hypermethylation can selectively silence multiple
promoters of steroid receptors in cancers. Mol Cell Endocrinol.
202:201–207. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Takai N, Kawamata N, Walsh CS, et al:
Discovery of epigenetically masked tumor suppressor genes in
endometrial cancer. Mol Cancer Res. 3:261–269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Plumb JA, Strathdee G, Sludden J, Kaye SB
and Brown R: Reversal of drug resistance in human tumor xenografts
by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene
promoter. Cancer Res. 60:6039–6044. 2000.
|
|
92
|
Fu S, Hu W, Iyer R, et al: Phase 1b-2a
study to reverse platinum resistance through use of a
hypomethylating agent, azacitidine, in patients with
platinum-resistant or platinum-refractory epithelial ovarian
cancer. Cancer. 117:1661–1669. 2011. View Article : Google Scholar
|
|
93
|
Fang F, Balch C, Schilder J, et al: A
phase 1 and pharmacodynamic study of decitabine in combination with
carboplatin in patients with recurrent, platinum-resistant,
epithelial ovarian cancer. Cancer. 116:4043–4053. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Chen H, Hardy TM and Tollefsbol TO:
Epigenomics of ovarian cancer and its chemoprevention. Front Genet.
2:672011. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Terasawa K, Sagae S, Toyota M, et al:
Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer
Res. 10:2000–2006. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Shi H, Wei SH, Leu YW, et al: Triple
analysis of the cancer epigenome: an integrated microarray system
for assessing gene expression, DNA methylation, and histone
acetylation. Cancer Res. 63:2164–2171. 2003.PubMed/NCBI
|
|
97
|
Appleton K, Mackay HJ, Judson I, et al:
Phase I and pharmacodynamic trial of the DNA methyltransferase
inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol.
25:4603–4609. 2007. View Article : Google Scholar : PubMed/NCBI
|
